Druggable Molecular Networks in BRCA1/BRCA2-Mutated Breast Cancer

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Mutations in tumor suppressor genes BRCA1 and BRCA2 are linked to aggressive triple-negative breast cancer (TNBC).
• TNBC is characterized by the absence of estrogen, progesterone, and human epidermal growth factor receptor 2, making it difficult to treat.

Purpose of the Study:

• To elucidate the metabolic and genetic connections underlying BRCA1/BRCA2 mutations.
• To explore the relationship between these mutations and effective therapeutic strategies.
• To identify novel drug targets for BRCA-mutated cancers.

Main Methods:

• Bibliographic analysis of PubMed-NCBI articles using Cytoscape software to construct gene networks.
• Identification of genes deregulated by BRCA mutations and modulated by therapies.
• Evaluation of the efficacy of targeted therapies in BRCA1/BRCA2-mutated cells.

Main Results:

• 98 genes were found to be deregulated by BRCA mutations, with 24 modulated by therapies.
• Specific genes like BIRC5, SIRT1, MYC, EZH2, CSN2 (BRCA1) and BCL2, BAX, BRIP1 (BRCA2) were identified.
• Therapies such as CDDO-Imidazolide, resveratrol, 3-deazaneplanocin A, genistein, daidzein, and PARP inhibitors showed selective efficacy against BRCA-mutated cells.
• Ferroptosis and proteoglycan pathways emerged as potential therapeutic targets.

Conclusions:

• BRCA1/BRCA2 mutations create vulnerabilities that can be exploited by targeted therapies.
• Understanding gene networks and pathway alterations is crucial for developing effective treatments for TNBC.
• Ferroptosis and proteoglycan pathways represent promising avenues for future drug development in BRCA-mutated cancers.